Skip Navigation Links
Company Intelligence: Schering-Plough

Schering-Plough | Company Structure Information from ICIS


In November 2009, Merck & Co and Schering-Plough completed its planned merger. The merged companies will operate under the Merck name.


Download the The ICIS Top 100 Chemical Companies listing here




In November 2007, Akzo Nobel completed the sale of Organon BioSciences to Schering-Plough for Euro11bn. The sale was completed after approval was given by the US Federal Trade Commission and the European Commission.


Organon BioSciences


Organon BioSciences is a global biopharmaceutical group, comprising of Organon and Intervet. It develops, manufactures and markets medicines for human and animal healthcare.  It has headquarters in Oss, the Netherlands and employs approximately 19,200 people, of whom 17% worked in research and development.


Organon - This is an international player in several key areas of human pharmaceuticals. It is a medium ranking pharmaceutical company with a therapeutic focus on hormonal and central nervous system (CNS) products. Product groups are contraception, hormone replacement treatment, infertility, depression and hospital pharmaceuticals.


Intervet - This is an animal healthcare company with vaccines and speciality products for both livestock and pets. The acquisition of Hoechst Roussel Vet and Bayer's North American biologicals products business is claimed to have pushed Intervet into the number three position worldwide.


Nobilon - This business deals in the development, licensing and manufacturing of human vaccines. It combines the technical, regulatory and product development capabilities of both Organon and Intervet.


Schering-Plough Research Institute


Schering-Plough Research Institute (SPRI) is the pharmaceutical research and development unit of Schering-Plough. With its New Jersey laboratories and DNAX Research Institute and Canji in California, SPRI carries out immunology and biotechnology research and gene therapy.


Schering-Plough Pharmaceuticals


Schering-Plough Pharmaceuticals manufactures and markets prescription pharmaceuticals under its Schering Laboratories and Key Pharmaceuticals labels in the US and through subsidiaries in over 125 world markets. Products are offered primarily in four major therapeutic areas: allergy/respiratory, anti-infective/anticancer, dermatological and cardiovascular. A line of generic drugs is marketed in the US through the Warrick Pharmaceuticals unit.


Schering-Plough Animal Health


Schering-Plough Animal Health develops and markets worldwide a broad range of pharmaceuticals and biologicals for food-producing animals, including cattle, swine, poultry, sheep and fish, as well as for companion animals such as cats, dogs and horses. A major challenge for Schering-Plough Animal Health in 1998 was completing the integration of Mallinckrodt's worldwide animal health business, acquired in June 1997.


Schering-Plough HealthCare


Schering-Plough HealthCare Products is building on its position in North America as a manufacturer and marketer of over-the-counter (OTC) pharmaceutical and personal care products by capitalising on brand names as Afrin, Drixoral, Tinactin, Correctol, Dr. Scholl's and Coppertone in its OTC, foot care and sun care businesses.

Schering-Plough Strategy & Financial Highlights

In August 2009, Schering-Plough approved the merger with Merck & Co. It is believed that by combining the two companies it will create a “strong global health care leader”. Under the name “Merck”, the combined company will be headed by Merck chairman, president and chief executive officer, Richard Clark and have headquarters in Whitehouse Station, New Jersey, US. ICIS also provides you with key financial data listed in table form. More about Schering-Plough Strategy & Financial Highlights


Get news on Schering-Plough plus the latest chemical news, information, data, market movements and analysis in one place with ICIS news


Find details on other chemical companies and suppliers with ICIS search


ICIS offers a range of FREE e-newsletters to ensure that you don't miss out on the latest development and key market intelligence in your industry. If you want the latest news sent to your inbox, sign up for ICIS e-newsletters today.

Plants and projects:

Find out more about current and planned chemical plants and projects by subscribing to our comprehensive database

Free trial to ICIS
Simon Robinson - The Big Biofuels Blog
For some independent thinking on the burgeoning world of biofuels, click into Simon Robinson's The Big Biofuels Blog here.


INSIGHT: China may see major ethylene shortfall by 2019
"At $50-90/bbl for Brent, UBS estimates the internal rate of return (IRR) for China CTO/MTO projects range from 5-10% – mostly too low to justify inve more

VIDEO: ICIS Special Report: Innovation is key to success


We welcome your feedback. Please feel free to send us your comments on any aspect of this site. Click here to make your comments.